Company Overview

Enlivex Ltd. is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapy treatments for life-threatening inflammatory conditions. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immune modulation rather than pathogen-specific therapies. Enlivex’s core therapeutic approach targets immune system balance, aiming to address conditions characterized by excessive or dysregulated immune responses.

The company’s principal product candidate is Allocetra™, an off-the-shelf cell therapy derived from apoptotic cells designed to rebalance immune responses. Allocetra™ represents Enlivex’s primary revenue driver prospect and strategic focus, as the company does not yet generate commercial product revenue. Enlivex was founded based on academic research originating in Israel and has evolved from early translational research into a publicly traded company listed on NASDAQ under the ticker ENLV, advancing its lead asset through multiple clinical indications.

Business Operations

Enlivex operates as a single-reportable-segment company focused on biopharmaceutical research and development. Its business model centers on the discovery, clinical development, and potential commercialization of cell-based therapies, with current operations dedicated primarily to advancing Allocetra™ through clinical trials. The company does not have manufacturing commercialization at scale and relies on controlled production processes suitable for clinical-stage development.

Operations are conducted through Enlivex Therapeutics Ltd., which manages research activities, clinical trials, regulatory engagement, and intellectual property. Clinical development has included trials in sepsis, COVID-19-related complications, and other inflammatory conditions, conducted in both domestic and international settings. As of available public disclosures, Enlivex has not reported material joint ventures or revenue-generating partnerships, and its activities are funded primarily through equity financing and public market capital.

Strategic Position & Investments

Strategically, Enlivex positions itself within the emerging field of immune rebalancing therapies, distinguishing its approach from traditional anti-inflammatory or antimicrobial treatments. Its growth strategy centers on expanding clinical indications for Allocetra™, progressing toward later-stage trials, and potentially pursuing regulatory approvals in major markets. The company has publicly emphasized sepsis and severe inflammatory conditions as its initial commercial targets due to high unmet medical need.

Enlivex’s investments are concentrated in clinical trials, regulatory preparation, and intellectual property protection related to Allocetra™. The company has not disclosed any major acquisitions or a diversified portfolio of subsidiaries, and its pipeline beyond Allocetra™ remains limited based on publicly available information. Data inconclusive based on available public sources regarding material investments in external portfolio companies or advanced-stage acquisition activity.

Geographic Footprint

Enlivex is headquartered in Israel, which serves as the center of its research, corporate management, and strategic decision-making. The company maintains a clinical and regulatory presence in North America and Europe through the conduct of multinational clinical trials and engagement with regulatory authorities.

While Enlivex does not report large-scale commercial operations, its geographic footprint reflects an international development strategy aimed at accessing major healthcare markets. Clinical trial sites and regulatory planning indicate a focus on the United States, Israel, and select European regions, positioning the company for potential global commercialization if regulatory milestones are achieved.

Leadership & Governance

Enlivex was founded by Prof. Dror Mevorach, whose academic research underpins the company’s core technology and scientific strategy. The leadership team combines clinical, scientific, and capital markets experience, with a governance structure typical of a publicly traded clinical-stage biotechnology company.

Key executives include:

• Oren Hershkovitz – Chief Executive Officer
• Prof. Dror Mevorach – Founder and Chief Scientific Officer
• Hagai Ben-Yehuda – Chief Financial Officer

The leadership’s stated strategic vision emphasizes rigorous clinical validation, cautious capital allocation, and the advancement of immune-modulating therapies to address high-mortality inflammatory conditions. Governance practices and executive oversight are conducted in accordance with NASDAQ listing standards and applicable securities regulations.